{
    "nct_id": "NCT05557708",
    "official_title": "Phase 1 Trial of Dosimetry Guided 212Pb-pentixather Radioligand Therapy in Patients With Atypical Lung Carcinoids and Neuroendocrine Carcinomas",
    "inclusion_criteria": "* ability to provide independent consent\n* adequate bone marrow function (platelet count ≥ 100,000; hemoglobin of ≥ 10 g/dL; neutrophil count ≥ 1,500 cells/mm3)\n* adequate kidney function (creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault equation\n* adequate liver function (serum bilirubin ≤ 3x the upper limit of normal, AST ≤ 5x the upper limit of normal, and ALT ≤ 5x the upper limit of normal)\n* failed initial therapy or declined further therapy known to confer benefit\n* have at least one lesion ≥ 2 cm that is positive for CXCR4 as demonstrated by Lead-203 Pentixather SPECT/CT\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* major surgery within 4 weeks of consent\n* antoher investigational agent within 4 weeks of consent\n* uncontrolled illness including, but not limited to, ongoing or active infection that would necessitate a delay in therapy or cause a hospital admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic cirrhosis or severe impairment, or psychiatric illness/social situations that would limit compliance with study requirements.\n* prior solid organ transplant\n* cytotoxic or antineoplastic therapy within 21 days of consent (42 days for nitrosoureas)\n* antibody therapy within the 21 days of consent\n* allogenic bone marrow or stem cell transplant, or any stem cell infusion, within 84 days of consent\n* pregnancy\n* breastfeeding\n* refusal to comply with birth control requirements during study",
    "miscellaneous_criteria": ""
}